Type 2 Inflammation Biologic (Anti-IL-5) from Teva Pharmaceuticals.
Cinqair is an IL-5 inhibitor for severe eosinophilic asthma. Unlike Nucala, it is administered intravenously, which may be preferred for patients who would benefit from in-office dosing or have very high eosinophil levels.
Cinqair is FDA-approved for the following indications:
Cinqair is administered as an intravenous infusion every four weeks, typically at a partner infusion center.
The manufacturer offers a patient support program — Teva Shared Solutions / Cinqair Patient Support — that can help with insurance navigation, copay assistance for eligible patients, nursing support, and ongoing education. More information is available at https://www.tevashareassist.com.
Treatment with Cinqair is initiated and monitored by Dr. McNeil. Prior authorizations are handled in-house — patients are not asked to navigate insurance approvals on their own. Infusion logistics are coordinated through trusted partner infusion providers — including Horizon Infusions, where the practice is co-located — or arranged for home infusion when appropriate. The team handles scheduling, nursing coordination, and prior-authorization renewals.
Important safety note: This page is not a substitute for the FDA prescribing information. Risks, contraindications, drug interactions, and required monitoring vary by patient. The official manufacturer website (https://www.cinqair.com) provides the most current full prescribing and safety information. Treatment decisions and monitoring are individualized — please discuss with Dr. McNeil whether Cinqair is appropriate for your situation.
Donald L. McNeil, MD · Board Certified in Allergy & Immunology and Internal Medicine
This page is provided for educational purposes only and is not medical advice. If you have an emergency, call 911.